Enliven Therapeutics Reports the PoC Data from the P-I Study of ELVN-001 as a Treatment of Chronic Myeloid Leukemia
Shots:
- The P-I study evaluates the safety, tolerability, PK characteristics & recommended dosing of ELVN-001 (10mg to 120mg, QD) to treat CML patients (n=27) with & without T315I mutations and those who are relapsed, refractory or intolerant to TKIs
- The study, as of Mar 2024 among 16 evaluable patients, demonstrated a cumulative MMR rate of 44% & 40% in post-asciminib as well as TKI-resistant patients, respectively along with an improvement in BCR::ABL1 transcript levels among response-evaluable patients by 12wks.
- Furthermore, the PK profile favored QD dosing & the target coverage of ELVN-001 at dosing level ≥40mg QD was superior over 2nd generation TKIs while it was similar to asciminib at 80mg QD
Ref: Terns Pharmaceuticals | Image: Terns Pharmaceuticals
Related News:- Terns Pharmaceuticals’ TERN-701 Receives the US FDA’s Orphan Drug Designation to Treat Chronic Myeloid Leukemia
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
